Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 62Terminated 13Unknown 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 208Leukemia, Lymphocytic, Chronic, B-Cell 136Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Hematologic Neoplasms 113Myelodysplastic Syndromes 96Leukemia 82Lymphoma 65Lymphoma, Non-Hodgkin 57Multiple Myeloma 43Leukemia, Myelogenous, Chronic, BCR-ABL Positive 37Leukemia, Myelomonocytic, Chronic 35Neoplasms 31Recurrence 27Myeloproliferative Disorders 27Burkitt Lymphoma 25Lymphoma, Mantle-Cell 23Leukemia, Biphenotypic, Acute 23Lymphoma, Large B-Cell, Diffuse 22Lymphoma, Follicular 20Lymphoma, B-Cell, Marginal Zone 20Lymphoma, B-Cell 20Leukemia, Myeloid, Chronic-Phase 16Leukemia, B-Cell 16Hodgkin Disease 16Primary Myelofibrosis 15Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Waldenstrom Macroglobulinemia 14Hematologic Diseases 14Anemia, Refractory, with Excess of Blasts 11Neoplasm, Residual 9

Interventions

Vorinostat 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Anemia, Refractory × Other hematologic neoplasm × Clear all
NCT00392353 2026-04-13

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
135 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡